US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

17.72

+1.609.93%

Post-market: 17.880.1600+0.90%18:37 EDT

Volume:2.50M

Turnover:43.12M

Market Cap:2.27B

PE:-5.41

High:17.99

Open:16.67

Low:16.03

Close:16.12

52wk High:18.18

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:2.78

T/O Rate:4.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:4.98

PE(LYR):-3.56

Loading ...

Overview Company News Filings

Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss

MT Newswires Live

Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028

THOMSON REUTERS

Generate Biomedicines Inc - Q1 Revenue $7.2 Mln

THOMSON REUTERS

Generate Biomedicines Inc: Expects to Require Additional Capital to Support Long-Term Operations

THOMSON REUTERS

Press Release: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q1 FY26 net loss widens to $61.7 million; revenue falls to $7.2 million

Generate Biomedicines Initiated at Buy by HC Wainwright & Co.

Generate Biomedicines initiated with a Buy at H.C. Wainwright

Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug

Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Generate Biomedicines Initiated at Overweight by Piper Sandler

Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS

Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating

MT Newswires Live

Generate Biomedicines Initiated at Buy by Guggenheim

Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/GENB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":17.72,"timestamp":1787601600000,"preClose":16.12,"halted":0,"volume":2499749,"hourTrading":{"tag":"盘后","latestPrice":17.88,"preClose":17.72,"latestTime":"18:37 EDT","volume":21051,"amount":373033.992888,"timestamp":1787611044381,"change":0.16,"changeRate":0.009029,"amplitude":0.043454},"delay":0,"changeRate":0.09925558312655074,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Post-Mkt","change":1.6,"latestTime":"08-24 18:41:05 EDT","open":16.67,"high":17.985,"low":16.03,"amount":43120922.724649005,"amplitude":0.121278,"askPrice":18,"askSize":290,"bidPrice":17.23,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":16.12,"preHourTrading":{"tag":"盘前","latestPrice":16.56,"preClose":16.12,"latestTime":"09:28 EDT","volume":377,"amount":6154.609447999999,"timestamp":1787578095129,"change":0.44,"changeRate":0.027295,"amplitude":0.028766},"postHourTrading":{"tag":"盘后","latestPrice":17.88,"preClose":17.72,"latestTime":"18:37 EDT","volume":21051,"amount":373033.992888,"timestamp":1787611044381,"change":0.16,"changeRate":0.009029,"amplitude":0.043454},"volumeRatio":2.776675},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":2.776675,"shares":128192484,"dividePrice":0,"high":17.985,"amplitude":0.121278,"preClose":16.12,"low":16.03,"week52Low":11,"pbRate":"4.98","psRate":"85.77","week52High":18.18,"institutionHeld":0,"latestPrice":17.72,"committee":-0.183673,"eps":-3.27625,"divideRate":0,"volume":2499749,"delay":0,"ttmEps":-3.27625,"open":16.67,"prevYearClose":16,"prevWeekClose":16.12,"prevMonthClose":14,"prevQuarterClose":16.87,"fiveDayClose":15.69,"twentyDayClose":13.68,"sixtyDayClose":13.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-08-21","current":-4.920259,"percent":0.191667,"low":-10.037721,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"high":-6.883628,"avg":-8.104092,"sd":0.705945,"marketCap":2052355451},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451}],"updateTime":1787571457218},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633945500","title":"Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945500","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633945500?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:11","pubTimestamp":1778242260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 08:11 ET (12:11 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633159146","title":"Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633159146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633159146?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:16","pubTimestamp":1778152597,"startTime":"0","endTime":"0","summary":"“We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform,” sa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-reports-q1-revenue-7-22m-consensus-4-75m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-reports-q1-revenue-7-22m-consensus-4-75m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111704","title":"Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633111704?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:22","pubTimestamp":1778149353,"startTime":"0","endTime":"0","summary":"Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633770117","title":"Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2633770117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633770117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633707117","title":"Generate Biomedicines Inc - Q1 Revenue $7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633707117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633707117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633705117","title":"Generate Biomedicines Inc: Expects to Require Additional Capital to Support Long-Term Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2633705117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633705117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA7TQMZK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633248117","title":"Press Release: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633248117","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633248117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:17","pubTimestamp":1778149020,"startTime":"0","endTime":"0","summary":"-- SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 . -- Clinical trial sites activated for GB-4362 ; first. patient dosing is expected in mid-2026; program has received FDA Fast. -- First patient dosing is expected in the second half of 2026 for GB-5267. SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc.   today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.Generate's GB-5267  program, developed in collaboration with Roswell Park Comprehensive Cancer Center, is expected to dose the first patient in the second half of 2026 in a Phase 1 clinical trial in solid tumors, initially targeting ovarian cancer.Cash, cash equivalents, and marketable securities were $516.6 million as of March 31, 2026, compared with $221.5 million as of December 31, 2025. The cash, cash equivalents, and marketable securities as of March 31, 2026, reflects $369.3 million in net proceeds from Generat","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIE","BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633122117","title":"Generate Biomedicines Q1 FY26 net loss widens to $61.7 million; revenue falls to $7.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633122117","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633122117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:13","pubTimestamp":1778148829,"startTime":"0","endTime":"0","summary":"Generate Biomedicines posted a first-quarter net loss of $61.7 million, widening from $44.3 million a year earlier, as revenue slipped 18% to $7.2 million.Research and development expense climbed 24% to $57.8 million, driven by continued investment in the GB-0895 Phase 3 severe asthma program plus higher personnel-related costs.Cash, cash equivalents, and marketable securities jumped to $516.6 million as of March 31 from $221.5 million at year-end, reflecting $369.3 million in net IPO proceeds; runway seen into first half of 2028.GB-0895 Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials continued to advance, while GB-4362 clinical sites were activated with first patient dosing expected mid-2026 and GB-5267 first dosing expected in second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL26sKRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627243466","title":"Generate Biomedicines Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2627243466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627243466?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:37","pubTimestamp":1776076620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 06:37 ET (10:37 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627043141","title":"Generate Biomedicines initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2627043141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627043141?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:18","pubTimestamp":1776075525,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $16 price target The stock has fal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626112969","title":"Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2626112969","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626112969?lang=en_us&edition=fundamental","pubTime":"2026-04-11 01:45","pubTimestamp":1775843123,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Generate Biomedicines, Inc., with a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-generate-biomedicines-driven-by-differentiated-pipeline-gb-0895-asthma-opportunity-and-ai-enabled-protein-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-generate-biomedicines-driven-by-differentiated-pipeline-gb-0895-asthma-opportunity-and-ai-enabled-protein-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","CHAT","AIPO","GENB","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494368","title":"Generate Biomedicines publishes corporate presentation on programmable biology drug design platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494368?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:07","pubTimestamp":1775646420,"startTime":"0","endTime":"0","summary":"Generate Biomedicines outlined strategy to use generative biology and scaled lab automation to lower drug-discovery time to proof of concept to 3-5 years from 6-8 years.Company also projected cost to proof of concept of $25-60 million versus $380 million for traditional discovery.Lead program GB-0895, anti-TSLP monoclonal antibody, is positioned for twice-yearly dosing with reported human half-life of 98 days.GB-0895 is in Phase 3 development in severe asthma, with Phase 1b results in moderate-to-severe COPD slated for 1H 2026.Pipeline catalyst slate includes planned Phase 1 first-patient-dosed starts in 1H 2026 for GB-4362, an MMAE toxin neutralizer, in first-line metastatic urothelial cancer, alongside GB-5267 MUC-16 armored CAR-T in relapsed or refractory platinum-resistant ovarian cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1MDjP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622006872","title":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006872","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006872?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:52","pubTimestamp":1774461124,"startTime":"0","endTime":"0","summary":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an \"overweight\" rating as research quiet period ends** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial ** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering** As of last close, stock down 24% since its debut on Feb. 27  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","PIPR","LU0053671581.USD","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077173","title":"Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077173","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077173?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:45","pubTimestamp":1774449917,"startTime":"0","endTime":"0","summary":"Salveen Richter, an analyst from Goldman Sachs, has initiated a new Buy rating on Generate Biomedicines, Inc. (GENB). Salveen Richter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","GENB","AIPO","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FANG","DINO","BAM","CEGX","ELVN","APEI","KBH","AFG","AVTX","GENB","CVI","AIR","ARE","CNM","HAL","AVAH","BZAI","BP","AMZD","BRZE","USAW.SI","AMZN","BTM","BXP","AARD","CDE","CEG","BWXT","AZYY","MTDR","AMZP","HD","BCAX","ACAD","CVX","BPH","FRPT","FIGG","ABSI","DK","ADUS","EVGO","FIG","DG","ESE","GLW","CALM","AMZU","INSM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621706775","title":"Generate Biomedicines Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706775?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:02","pubTimestamp":1774357320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 09:02 ET (13:02 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621205062","title":"Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2621205062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621205062?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:44","pubTimestamp":1774356269,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061288","title":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061288?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:50","pubTimestamp":1774353049,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061159","title":"Generate Biomedicines Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061159?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:46","pubTimestamp":1774352760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:46 ET (11:46 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063010","title":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:17","pubTimestamp":1774347431,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":59,"code":"91000000","status":"200"}]}}